Benzinga | Feb 5, 2021 01:22PM EST

Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $119

Mizuho analyst Divan Vamil maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and raises the price target from $117 to $119.